migraines Word Scramble
|
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
| Question | Answer |
| receptors affected by chlorpromazine & prochlorperazine | DA, Ach, adrenergic, histaminergic |
| adverse effects of DA antagonists | poikilothermic, blurred vision, constipation, agranulocytosis, phototoxicity, EPS |
| 1 dose of sumatriptan = | aspirin + metoclopramide |
| NSAIDS most effective when | taken early on in an attack |
| benefit of nasal spray 5HT1 agonists | faster and more effective relief |
| 5HT1 agonists + DA antagonists used for | severe acute attacks |
| amidrine = | acetaminophen + dichloralphenazone + isometheptene |
| potent vasoconstrictor | isometheptene |
| analgesic, anti-pyretic, and sedative drug | dichloralphenazone |
| propanolol use | prophylactic drug for migraines |
| pizotifen use | prophylactic drug for migraines |
| MOA of pizotifen | 5HT1, 2A, & 2C antagonist, with some anti-histamine/cholinergic effects |
| side effect of pizotifen | weight gain, drowsiness, anti-muscarinic effect |
| 3 major components of theory of cortical spreading depression | correlates to visual field distrubances, mediated by release of pro-inflam neuropeptides, involves activating of trigeminal afferents from dural vasculature |
| 3 major arguments for serotonin theory | anti-migraine agents are 5HT agonists/antagonists, increased risk of attack during resperpine/fenfluramine therapy |
| triptans & ergot alkaloids are.. 5HT agonists | |
| MOA of triptans | vasoconstriction & 5HT-1 mediated inhibition of CGRP |
| not effective in migraines w/aura until after the headache has already begun | triptans |
| contraindications of triptans | CV disease and cerebrovascular disease |
| receptors acted on by triptans | 5HT 1B & 1D |
| receptors acted on by ergot alkaloids | 5HT1 |
| contraindications of egot alkaloids | pregnancy, PAD, CAD, HTN, impaired renal/hepatic function |
| MOA of meteoclopramide | 5HT4 agonist, D2 antagonist, 5HT3 antagonist |
| helps w/nausea/vomitting in migraines | metoclopramide |
| adverse effects of metoclopramide | galactorrhea, constipation, EPS, tardive dyskinesia |
| contraindications for metclopramide | pheochromocytoma, PD |
| DA antagonists used to treat migraines chlorpromazine & prochlorperazine | |
| receptors affected by chlorpromazine & prochlorperazine | DA, Ach, adrenergic, histaminergic |
| adverse effects of DA antagonists | poikilothermic, blurred vision, constipation, agranulocytosis, phototoxicity, EPS |
| 1 dose of sumatriptan = | aspirin + metoclopramide |
| NSAIDS most effective when | taken early on in an attack |
| benefit of nasal spray 5HT1 agonists | faster and more effective relief |
| 5HT1 agonists + DA antagonists used for | severe acute attacks |
| amidrine = | acetaminophen + dichloralphenazone + isometheptene |
| potent vasoconstrictor | isometheptene |
| analgesic, anti-pyretic, and sedative drug | dichloralphenazone |
| propanolol use | prophylactic drug for migraines |
| pizotifen use | prophylactic drug for migraines |
| MOA of pizotifen | 5HT1, 2A, & 2C antagonist, with some anti-histamine/cholinergic effects |
| side effect of pizotifen | weight gain, drowsiness, anti-muscarinic effect |
| extremely potent vasodilator neuropeptide | calcitonin gene related peptide |
| most effecacious triptans | rizatriptan,eletriptan; sumatriptan, zolmitriptan |
| least efficacious triptans | naratriptan, frovatriptan |
| bromocriptine | ergot alkaloid |
| LSD | ergot alkaloid |
| methysergide | ergot alkaloid |
| agonists at 5HT and a1 receptors | ergot alkaloids |
| side effects of ergot alkaloids | leg weakness, muscle pain, numbness/tingling, GI issues, nausea |
| post partum hemorrhage | ergot alkaloids |
| metoclopramide | DA antagonists |
| clinical uses of chlorpromazine & prochlorpromazine | antiemetic, schizophrenia, tourette syn, huntington disease, dementia |
| butorphanol | narcotic |
| meperidine | narcotic |
| MOA of butorphanol | partial agonist @u, full agonist @k |
| administration of butorphanol | intranasal spray |
| administration of meperidine | IV |
| concern for addiction liability | oxycodone, hydrocodone, etc |
| zolmitriptan | 5HT1 agonist |
| dihydroergotamine | 5HT1 agonist |
| sumatriptan | 5HT1 agonist |
| acetaminophen + dichloralphenazone + isometheptene = | amidrine |
| MOA of amitriptyline, dothiepin, & nortriptyline | 5HT & NE reuptake inhibitors, block Na+ channels, |
| clinical uses of tricyclics | migraine prophylaxis, pain syn, chronic fatigue syn |
| may precipitate mania in bipolar pts | tricyclic antidepressants |
| clinical uses of valproic acid | generalized seizures, absence seizures, migraine prophylaxis |
| MOA of valproid acid | prolongs inactive state of Na+ channels, inhibits Ca++ channels, increases GABA |
| MOA ofgabapentin | inhibits ca++ channels |
| may be associated with withdrawl sx | gabapentin |
| MOA of methysergide | 5HT2 & 5HT1A antagonist |
| retroperitoneal fibrosis | methysergide |
| clinical uses of methysergide | migraine prophylaxis, severe refractory migraines, cluster headaches |
| migraine prophylaxis drugs | propranolol, pizotifen, tricyclic Ads, valproic acid, gabapentin, methysergide |
| drugs for acute migraines | triptans, ergot alkaloids, DA antagonists, narcotics, combination |
Created by:
drhermy